JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB301015

Human ITGB2 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ITGB2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Next Generation Sequencing - Human ITGB2 knockout A549 cell line (AB301015)
  • NGS

Lab

Next Generation Sequencing - Human ITGB2 knockout A549 cell line (AB301015)

68 bp deletion after Phe 118 (allele 1); 19 bp deletion after Phe 118 of WT protein

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab301015-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab288558 Human wild-type A549 cell line", "number":"AB301015-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab301015 Human ITGB2 knockout A549 cell line", "number":"AB301015-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab301015-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab301015 Human ITGB2 knockout A549 cell line", "number":"AB301015-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ITGB2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD18 also known as ITGB2 is a protein with a molecular weight of approximately 95 kDa. It is part of the beta-2 integrin family and partners with different alpha subunits to form heterodimers. CD18 is primarily expressed on leukocytes including neutrophils monocytes macrophages and lymphocytes. As a surface marker CD18 plays a significant role in immune cell adhesion and migration enabling cells to respond to inflammation signals effectively.
Biological function summary

The CD18 protein functions in conjunction with associated alpha subunit partners forming a part of the wider integrin family complex. ItgB2 as it is sometimes referred to is essential for cell adhesion processes. These heterodimers facilitate binding between leukocytes and various ligands on endothelial cells which subsequently controls leukocyte transmigration through vascular walls. CD18's activities are critical in immune system responses making it a prominent focus in immunological research.

Pathways

The role of CD18 extends into inflammatory and immune response signaling pathways. It contributes critically to the leukocyte adhesion cascade. This cascade engagement involves interaction with other proteins such as ICAM-1 on endothelial surfaces. CD18 through its association in integrin-mediated signaling influences processes like phagocytosis and lymphocyte activation giving it a central place in cellular immunity.

Deficiencies or mutations affecting CD18 function correlate with disorders such as Leukocyte Adhesion Deficiency type I (LAD-I). This condition results from impaired leukocyte function due to defective integrin expression. The role of CD18 in arthritis is also significant primarily by mediating leukocyte infiltration into inflamed tissues. Its interaction with proteins like ICAM-1 becomes exceptionally relevant in these disease dynamics indicating potential therapeutic targets for modulating immune responses.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com